Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: A randomized controlled trial

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: A randomized controlled trial

Summary. Background:A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors. Patients/Methods:This global, prospective, randomized, double-blinded, active-controlled, do...

全面介紹

Saved in:
書目詳細資料
Main Authors: Erich V. de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, László Nemes, Silva Z. Šalek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Ampaiwan Chuansumrit
其他作者: Universidade Estadual de Campinas
格式: Article
出版: 2018
主題:
Medicine
在線閱讀:https://repository.li.mahidol.ac.th/handle/123456789/15121
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
機構: Mahidol University

因特網

https://repository.li.mahidol.ac.th/handle/123456789/15121

相似書籍